Hanmi Pharmaceutical Q3 Operating Profit Falls 31.3% Year Over Year

• Hanmi Pharmaceutical’s third-quarter 2026 consolidated operating profit fell 31.3% year over year to 37.81 billion won.
• Revenue rose 4.2% from a year earlier to 377.42 billion won.
• Net income dropped 69.1% year over year to 14.01 billion won.
• Compared with the previous quarter, operating profit declined 71.2%; revenue fell 19.2%.
• For the first nine months of 2026, operating profit increased 27.5% year over year to 222.55 billion won.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanmi Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261027800461), on October 27, 2026, and is solely responsible for the information contained therein.